Dual PET scans for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man 18 years or older
- You have prostate cancer that has spread to other parts of the body but still responds to hormone therapy (called mCSPC)
- Your cancer is either high volume on scans, or low volume with a PSA of 4.0 or higher after 6-8 months of hormone therapy
- You are willing to have two special PET scans (PSMA and FDG) at Princess Margaret Cancer Center in Toronto
- You have not had a PSMA or FDG PET scan in the last 60 days
- You can follow the study procedures and do not have other serious health issues that would interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a European registry that collects information from men with prostate cancer who need advanced imaging (like PSMA PET/CT or MRI) to check if the cancer has spread. By joining, you help researchers learn more about how these scans improve care.
This trial tests whether a special PET/MRI scan (using a tracer called 68Ga-PSMA-11) can better identify the main tumor in men with early prostate cancer who are planning surgery. The goal is to help doctors target treatment more precisely in the future.
This study looks at how well two different PSMA PET scans work for men with advanced prostate cancer. The scans help doctors see where the cancer is, which can guide treatment decisions and help you and your doctor plan next steps.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.